Literature DB >> 12532446

Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Bin-Wen Wu1, Yuan Wu, Jia-Long Wang, Ju-Sheng Lin, Shu-Yu Yuan, Ai Li, Wu-Ren Cui.   

Abstract

AIM: Many growth factors, such as epidermal growth factor (EGF), are associated with the carcinogenesis. EGF plays its role in the proliferation of hepatoma cells through binding with EGF receptor (EGFR) and a series of signal transduction. But the postreceptor pathway is still not clear. In the present experiment, we studied the effect of tyrosine kinase, protein kinase C, Na(+)/H(+) exchange, calmodulin and voltage-dependent Ca(2+) channel on EGF-induced hepatoma cell proliferation.
METHODS: Hepatoma cell line SMMC7721 was cultured in RPMI1640 serum-free medium. In order to study the effect of thyrosine kinase, protein kinase C, Na(+)/H(+) exchange, calmodulin and voltage-dependent Ca(2+) channel on human heptoma cell proliferation induced by epidermal growth factor (EGF), DNA synthesis rate of hepatoma cells was measured by the method of (3)H-TdR incorporation.
RESULTS: EGF (10(-9) M) stimulated the proliferation of heptoma cells significantly ((3)H-TdR incorporation was 1 880+/-281 cpm/well, P<0.05), and this effect was significantly inhibited by tyrosine kinase inhibitor genistein ((3)H-TdR incorporation was 808+/-209 cpm/well, P<0.001). Calmodulin inhibitor W-7, protein kinase C inhibitor H-7 and Na(+)/H(+) exchange inhibitor amiloride individually had significant inhibiting effect on EGF-induced proliferation of hepatoma cells ((3)H-TdR incorporation was 978+/-87.3 cpm/well, 1 241+/-147 cpm/well, 1 380+/-189 cpm/well, respectively, P<0.001, P<0.01, P<0.05), but they all had no effect on the basal level proliferation of cultured hepatoma cells ((3)H-TdR incorporation was 1 284+/-260 cpm/well, 1 179+/-150 cpm/well, 1 392+/-152 cpm/well, respectively, (3)H-TdR incorporation of the control was 1 353+/-175 cpm/well, P>0.05). Voltage-dependent Ca(2+) channel inhibitor verapamil had no inhibition on EGF-induced proliferation of hepatoma cells ((3)H-TdR incorporation was 1 637+/-133 cpm/well, P>0.05), it also had no effect on the basal level proliferation of cultured hepatoma cells ((3)H-TdR incorporation was 1 196+/-112 cpm/well, P>0.05).
CONCLUSION: Our data suggest that tyrosine kinase, Ca(2+)-calmodulin-dependent pathway, protein kinase C and Na(+)/H(+) exchange play a critical role in EGF-induced proliferation of hepatoma cells and that the effect of EGF is independent of voltage-dependent Ca(2+) channel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532446      PMCID: PMC4611326          DOI: 10.3748/wjg.v9.i2.271

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Sp1.

Authors:  X L Zheng; S Matsubara; C Diao; M D Hollenberg; N C Wong
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

2.  Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis.

Authors:  S Koyama; T Maruyama; S Adachi
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

3.  Retinoid and androgen regulation of cell growth, epidermal growth factor and retinoic acid receptors in normal and carcinoma rat prostate cells.

Authors:  F Richter; H F Huang; M T Li; D Danielpour; S L Wang; R J Irwin
Journal:  Mol Cell Endocrinol       Date:  1999-07-20       Impact factor: 4.102

4.  Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.

Authors:  K Harada; G Shiota; H Kawasaki
Journal:  Liver       Date:  1999-08

5.  Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells.

Authors:  I Baba; S Shirasawa; R Iwamoto; K Okumura; T Tsunoda; M Nishioka; K Fukuyama; K Yamamoto; E Mekada; T Sasazuki
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

6.  EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP.

Authors:  P Sundareshan; R B Nagle; G T Bowden
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

7.  Identification and characterization of receptor for mammalian hepatopoietin that is homologous to yeast ERV1.

Authors:  G Wang; X Yang; Y Zhang; Q Wang; H Chen; H Wei; G Xing; L Xie; Z Hu; C Zhang; D Fang; C Wu; F He
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

8.  Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin.

Authors:  Y Li; M Li; G Xing; Z Hu; Q Wang; C Dong; H Wei; G Fan; J Chen; X Yang; S Zhao; H Chen; K Guan; C Wu; C Zhang; F He
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

9.  Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma.

Authors:  M Miyaki; C Sato; K Sakai; M Konishi; K Tanaka; M Muraoka; R Kikuchi-Yanoshita; Y Nadaoka; H Kanda; T Kitagawa
Journal:  Int J Cancer       Date:  2000-02-15       Impact factor: 7.396

10.  p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

Authors:  J Schneider; P Presek; A Braun; P Bauer; N Konietzko; B Wiesner; H J Woitowitz
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

View more
  9 in total

1.  Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells.

Authors:  Zhi-Su Liu; Sheng-Li Tang; Zhong-Li Ai
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

2.  FT-IR spectroscopic analysis of normal and cancerous tissues of esophagus.

Authors:  Jian-Sheng Wang; Jing-Sen Shi; Yi-Zhuang Xu; Xiao-Yi Duan; Li Zhang; Jing Wang; Li-Ming Yang; Shi-Fu Weng; Jin-Guang Wu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

3.  Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.

Authors:  Bu-Dong Zhu; Shou-Jun Yuan; Qi-Cheng Zhao; Xin Li; Yan Li; Qi-Ying Lu
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.

Authors:  Caecilia Hc Sukowati; Natalia Rosso; Lory S Crocè; Claudio Tiribelli
Journal:  World J Hepatol       Date:  2010-03-27

5.  The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.

Authors:  Hongbing Li; Juan Sánchez-Torres; Alan Del Carpio; Valentina Salas; Antonio Villalobo
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

6.  Protective effect of angelica sinensis polysaccharide on experimental immunological colon injury in rats.

Authors:  Shao-Ping Liu; Wei-Guo Dong; Dong-Fang Wu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

7.  Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice.

Authors:  Bai-Jun Fang; Mei-Li Yu; Shao-Guang Yang; Lian-Ming Liao; Jie-Wen Liu; Robert C-H Zhao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

Review 8.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

9.  Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of tumor cells while they enhance attachment to the substrate.

Authors:  Juan Alcalde; María González-Muñoz; Antonio Villalobo
Journal:  Heliyon       Date:  2020-05-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.